Shalin Shah

So that single test can give you an insight into your cardiovascular health, your inflammation in your body, your glucose or your, you know,

metabolism there.

So again, a single test that's most important.

But to your question on the panel, there were three main takeaways.

One was screening.

So we should be screening every man for their testosterone levels for this, again, this biomarker insight that I'm mentioning.

Could it be for everyone over 40?

That's an easy number to pick, but it could be even earlier.

So you have a baseline.

Say you're 30 years old and everything's feeling great.

But at least you know, when I was 30, my testosterone level was maybe 750 nanovariants per deciliter.

So when I'm later in life too, not that you're treating to that number, but you understand your progression, right?

Because we're all on slightly different paths there.

And what might have been good for me might not have been your exact number.

There's a wide range there.

so testing is one.

The second is broader labels because the label right now, as you look at the, the, that's called the package insert on a product, like a product like our, say Kaiser tracks, um,

you know, it's indicated for a very narrow patient population.

And in fact, most of the men that are testosterone deficient fit a broader definition.

And it really doesn't matter.